Fig 3 - by Aihong Zheng (20571034)

Subjects:

Landmark prospective studies on the impact of T classification and LN involvement on the survival of AC. by Aihong Zheng (20571034)

Subjects:

S1 Fig - by Aihong Zheng (20571034)

Subjects:

A brief illustration of the revisions between AJCC TNM eighth and ninth editions. by Aihong Zheng (20571034)

Subjects:

Baseline clinical and treatment features of patients with LLA ASCC. by Aihong Zheng (20571034)

Subjects:

Fig 4 - by Aihong Zheng (20571034)

Subjects:

S2 Fig - by Aihong Zheng (20571034)

Subjects:

Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”

Data Sheet 1_A synonymous mutation of rs1137070 cause the mice Maoa gene transcription and translation to decrease.pdf by Kai Xin Li (19696741)

Data Sheet 1_Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.pdf by Jingjing Fang (124938)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Table 1_Higher oxidative balance score is associated with a decreased risk of infertility: an analysis of NHANES 2013–2020.docx by Mingjun Ma (11518765)

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”